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A B S T R A C T
Objective: To validate previously identified associations between radiological features and clinical features with
Epidermal Growth Factor Receptor (EGFR)/ Kirsten RAt Sarcoma (KRAS) alterations in an independent group of
patients with Non-Small Cell Lung Cancer (NSCLC).
Material and methods: A total of 122 patients with NSCLC tested for EGFR/KRAS alterations were included.
Clinical and radiological features were recorded.
Univariate analysis were performed to look at the associations of the studied features with EGFR/KRAS al-
terations. Previously calculated composite model parameters for each gene alteration prediction were applied to
this validation cohort. ROC (Receiver Operating Characteristic) curves were drawn using the previously vali-
dated composite models, and also for each significant individual characteristic of the previous training cohort
model. The Area Under the ROC Curve (AUC) with 95% Confidence Intervals (CI) was calculated and compared
between the full models.
Results: At univariate analysis, EGFR+ confirmed an association with an internal air bronchogram, pleural
retraction, emphysema and lack of smoking; KRAS+ with round shape, emphysema and smoking. The AUC
(95%CI) in the new cohort was confirmed to be high for EGFR+ prediction, with a value of: 0.82 (0.69-0.95) vs.
0.82 in the previous cohort, whereas it was smaller for KRAS+ prediction, with a value of 0.60 (0.48-0.72) vs.
0.67 in the previous cohort. Looking at single features in the new cohort, we found that the AUC for the models
including only smoking was similar to that of the full model (including radiological and clinical features) for
both gene alterations.
Conclusions: Although this study validated the significant association of clinical and radiological features
with EGFR/KRAS alterations, models based on these composite features are not superior to smoking history
alone to predict the mutations.
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1. Introduction
Non-Small Cell Lung Cancer (NSCLC) accounts for more than 85% of
all lung cancer cases, being the leading cause of cancer death among
men and woman in the US [1]. In the last decade, the advent of novel
therapeutics that specifically target signalling pathways activated by
genetic alterations has revolutionized the way patients with lung cancer
are treated. Recent practice guidelines in oncology and pathology re-
commend that all locally advanced and metastatic NSCLC with ade-
nocarcinoma histology undergo testing for the most common targetable
genetic abnormalities, such as Epidermal Growth Factor Receptor gene
(EGFR) mutations and Kirsten RAt Sarcoma viral oncogene homologue
(KRAS) rearrangements [2,3].
Radiomics is a high-throughput approach to translate medical
images into mineable data [4,5], including quantitative features, ex-
tracted by dedicated software, and visually assessed radiological char-
acteristics [6,7]. These imaging features may be then included along
with clinical and genomic data in more comprehensive prognostic
models [4,5,8]. Since the number of features is usually high, before
translation into clinical practice multisite trials are needed to validate
the results obtained in training cohorts on separate independent groups
of patients.
A previous study focused on the radiogenomics of NSCLC in a cohort
of 285 patients, and demonstrated that visually scored radiological
features are associated with tumour alterations, such as EGFR, KRAS
and ALK mutations [6].
The purpose of this study was to validate the previously developed
models for the prediction of EGFR and KRAS mutations, in an in-
dependent group of patients with lung adenocarcinoma tested for one
or both of these mutations.
2. Materials and methods
2.1. Patient selection
The training set consisted of a monocentric recruitment of 285 pa-
tients with lung adenocarcinoma tested for EGFR/KRAS alterations [6].
The cohort included in this study as a validation set consisted of an
external group of 122 patients from a different Institution with lung
adenocarcinoma tested for EGFR mutations and KRAS rearrangements.
The main inclusion criteria for both cohorts consisted of the availability
of a pretreatment chest CT study including the primary tumour, and the
availability of data on the EGFR mutation and/or KRAS rearrangement
status. This multicentric retrospective study received approval from the
Ethical Committees of both recruitment centres and an official agree-
ment was signed by both Institutions. For the training set, written in-
formed consent was obtained from all living patients; the local Ethical
Committee approved the use of anonymized data for the other patients,
waiving the informed consent (R422/16-IEO436).
2.2. CT features evaluation
For validation, the external centre sent the anonymised Digital
Imaging and Communications in Medicine (DICOM) images of the ex-
aminations along with the clinical data specified above. Two radi-
ologists with different degrees of experience in interpreting chest CT
images, both from the centre of the training cohort, independently
performed all qualitative image analyses. One radiologist was a senior
radiologist with 14 years of experience in thoracic imaging (SR); the
other radiologist was a fellow with three years of experience (FDP).
Doubts or uncertainties of the younger radiologist (FDP) were evaluated
in consensus with the senior radiologist (SR) and/or with the Head of
the Division (MB).
2.3. Data recorded
The date of CT examinations, age, sex, EGFR and/or KRAS status
were available for all patients; smoking status, when available, was
recorded. For each CT scan, anonymised for personal information but
unique because of the attribution of a serial number, the following data
were recorded and used for statistical analysis: 1) site of the lesion,
indicated as in Right Upper Lobe (RUL), Middle Lobe (ML), Right Lower
Lobe (RLL), Left Upper Lobe (LUL), Left Lower Lobe (LLL), and mixed
when infiltrating more than one lobe; 2) maximum diameter of the
lesion in any of the three planes evaluated on the multiplanar re-
constructed images with a soft tissue window; 3) shape, indicated as
complex, round or oval; 4) margins, evaluated in the lung window, and
indicated as smooth, lobulated or spiculated/irregular; 5) presence or
absence of a peripheral ground-glass opacity; 6) density, indicated as
partially solid or solid; 7) presence or absence of cavitation; 8) presence
or absence of an internal air bronchogram; 9) thickening of the adjacent
pleura (fissural or peripheral pleura); 10) presence or absence of in-
tratumoral necrosis; 11) presence or absence of suspicious satellite
nodules in the primary tumour lobe; 12) presence or absence of sus-
picious satellite nodules in non-tumour lobes; 13) presence or absence
of pleural retraction; 14) location of the lesion, as central or peripheral;
15) presence or absence of nodular calcifications; 16) presence or ab-
sence of emphysema; 17) presence or absence of fibrosis; 18) presence
or absence of pleural contact; 19) presence or absence of pleural effu-
sion (Fig. 1).
2.4. Statistical analysis
Radiological features and clinical characteristics were expressed as
mean and standard deviation for continuous variables (age and max-
imum diameter), and as frequency and percentage for categorical
variables. The characteristics of the training and validation cohorts
were compared using t-test for continuous variables and chi-square test
for categorical variables.
The multivariate prediction models previously obtained in the
training cohort [6] for EGFR and KRAS mutation/rearrangement were,
respectively:
−1.2103 −0.2136*(maximum diameter [cm]) +0.8882*(females)
+1.5168*(air bronchogram) +0.9183*(pleural retraction)
−1.3695*(fibrosis) −1.7150(smoking)
and
−2.0544 + 0.6071*(complex shape) +0.8756*(round shape)
+0.6389*(nodules in non-tumour lobes) +0.7936*(smoking)
where the coefficients are multiplied by 1 if the condition is present and
by 0 if the condition is absent, except for diameter, expressed in cm.
The above parameter estimates were here applied to the validation
cohort, and each patient was scored according to these models. The
corresponding Receiver Operating Curves (ROC) were drawn for each
gene mutation/rearrangement prediction, and the Area Under the
Curve (AUC) was calculated. In the training cohort we calculated, for
each gene mutation/rearrangement, the optimum cut-off that max-
imized Sensitivity (SE) + Specificity (SP). We then reported SE, SP and
Diagnostic Accuracy (DA), with exact 95% Confidence Intervals (CI),
obtained by applying this optimum cut-off to the validation cohort.
The univariate associations of clinical and radiological features with
the EGFR mutation and KRAS rearrangement in the validation cohort
was evaluated by using t-test for continuous variables and chi-square
test for categorical variables.
In order to evaluate the relative impact of each single predictor,
univariate prediction models were also applied to the validation cohort
and the corresponding AUC was calculated for each gene mutation/
rearrangement. Univariate and multivariable ROC curves for EGFR
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mutations and KRAS rearrangement prediction in the validation cohort
were thus compared with the test described in DeLong et al. [9] on the
subset of subjects with complete data on all variables included in the
full model. Calibration, which compares the predicted risk in an in-
terval versus the average risk score in an interval, was graphically re-
presented by calibration plots and assessed by Hosmer & Lemeshow
test. In order to have reliable risk estimates, we used five intervals
(possibly including 15 patients each) to draw the calibration plot. P-
values < 0.05 were considered statistically significant. The analysis
was performed with SAS Software (SAS Institute Inc., Cary, USA),
version 9.4.
Calibration analysis was performed with R software, version 3.4.0.
3. Results
CT and clinical characteristics of the training set (n = 285) and
validation set (n = 122) are included and compared in Table 1. The
training and validation sets showed significant differences for age
Fig. 1. Examples of the radiological qualitative features assessed.
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(mean ± SD: 65.21 ± 9.58 and 61.80 ± 11.52, respectively); sex
(more males in the training set and more female in the validation set;
M:F = 160:125 and M:F = 49:73, respectively); location of lesion in
lobes (more frequent in RUL and in LUL, respectively); central location
(more frequent in the validation set); and margins (less lobulated
margins in the validation set). Patients from the validation set pre-
sented more frequently with a thickening of adjacent pleura, pleural
retraction, emphysema, pleural contact, pleural effusion and EGFR
mutation, whereas cavitation and calcifications were less common.
Smoking status information was available in the validation set only for
88/122 (72%) patients, and it was positive for 74/88 (84%).
The ROC curve for EGFR mutation prediction in the validation set,
applying the prediction model previously obtained in the training set, is
shown in Fig. 2. The AUC (95% CI) for the validation set was 0.82
(0.69–0.95), as the AUC of the training set (0.82 [6]). The correspon-
dent calibration plot is shown in Supplementary Fig. 1. With a cut-off
for the model score of −1.21923, 14/20 EGFR+ patients in the vali-
dation cohort were correctly identified (SE; 95%CI = 70%; 46–88%)
and 52/63 EGFR– patients in the validation cohort were correctly
identified (SP; 95%CI = 83%; 71–91%), with DA (95%CI) = 80%
(69–88%).
The ROC curve for KRAS rearrangement prediction in the validation
set, applying the prediction model previously obtained in the training
set, is shown in Fig. 3. The AUC (95%CI) for the validation set is 0.60
(0.48–0.72), slightly smaller than that calculated in the training set
(0.67 [6]).
The correspondent calibration plot is shown in Supplementary
Fig. 2. With a cut-off for the model score of −0.8384, 32/41 KRAS+
patients in the validation cohort were correctly identified (SE;
95%CI = 78%; 62–89%) and 17/47 KRAS– patients in the validation
cohort were correctly identified (SP; 95%CI = 36%; 23–51%), with DA
(95%CI) = 56%(45–66%).
The univariate association of CT and clinical features with the EGFR
mutation in the validation set is shown in Table 2. Compared to the
training set [6], the EGFR+ mutation confirmed an association with an
internal air bronchogram, pleural retraction, and absence of emphy-
sema and of smoking. Smoking was the most associated factor, with
almost all EGFR- patients being smokers (65/67; 97%) compared to 9
smokers out of 21 EGFR+ patients (43%).
Fig. 4 shows ROC curves for EGFR mutation prediction in the vali-
dation set, showing that, as previously demonstrated in the training set,
the AUC for the full model (including both radiological and clinical
features) is significantly higher than that of each characteristic
(p < 0.003 for all comparisons) except smoking (p = 0.59).
Table 1
CT and clinical characteristics of the study populations in the training and validation sets.
Variable Training set
N (%)
Validation set
N (%)
P-value*
Maximum diameter (mm)^ 45.49 ( ± 26.27) 49.78 ( ± 26.45) 0.14
Age^ 65.21 ( ± 9.58) 61.80 ( ± 11.52) 0.005
Sex 0.003
Male 160/285 (56.14%) 49/122 (40.16%)
Female 125/285 (44.86%) 73/122 (59.84%)
Lobe 0.0002
RUL 99/285 (34.74%) 27/120 (22.50%)
ML 16/285 (5.61%) 1/120 (0.83%)
RLL 40/285 (14.04%) 30/120 (25.00%)
LUL 83/285 (29.12%) 36/120 (30.00%)
LLL 42/285 (14.74%) 16/120 (13.33%)
Mixed 5/285 (1.75%) 10/120 (8.33%)
Shape 0.06
Complex 91/285 (31.93%) 53/122 (43.44%)
Round 60/285 (21.05%) 18/122 (14.75%)
Oval 134/285 (47.02%) 51/122 (41.80%)
Margins 0.002
Smooth 45/285 (15.79%) 17/122 (13.93%)
Lobulated 49/285 (17.19%) 6/122 (4.92%)
Spiculated/irregular 191/285 (67.02%) 99/122 (81.15%)
Ground-glass opacity 55/285 (19.30%) 14/122 (11.48%) 0.05
Density 0.19
Subsolid 33/283 (11.66%) 9/122 (7.38%)
Solid 250/283 (88.34%) 113/122 (92.62%)
Cavitation 48/284 (16.90%) 10/122 (8.20%) 0.02
Air bronchogram 115/284 (40.49%) 43/122 (35.25%) 0.32
Thickening of the adjacent pleura 136/285 (47.72%) 72/119 (60.50%) 0.02
Necrosis 59/285 (20.70%) 28/122 (22.95%) 0.61
Satellite nodules in primary tumour lobe 95/284 (33.45%) 48/122 (39.34%) 0.25
Nodules in non-tumour lobes 114/285 (40.00%) 60/122 (49.18%) 0.09
Pleural retraction 142/284 (50.00%) 94/122 (77.05%) <0.0001
Lesion location 0.04
Central 106/283 (37.46%) 58/120 (48.33%)
Peripheral 177/283 (62.54%) 62/120 (51.67%)
Calcifications 32/284 (11.27%) 3/122 (2.46%) 0.004
Emphysema 52/285 (18.25%) 36/121 (29.75%) 0.01
Fibrosis 36/284 (12.68%) 18/120 (15.00%) 0.53
Pleural contact 181/285 (63.51%) 91/121 (75.21%) 0.02
Pleural effusion 47/285 (16.49%) 40/122 (32.79%) 0.0002
Smoking 133/261 (50.96%) 74/88 (84.09%) <0.0001
EGFR+ 60/280 (21.43%) 48/122 (39.34%) 0.0002
KRAS+ 64/240 (26.67%) 44/122 (36.07%) 0.06
LLL = Left Lower Lobe; LUL = Left Upper Lobe; ML = Medium Lobe; RLL = Right Lower Lobe; RUL = Right Upper Lobe.
* T-test for continuous variables; Chi-Square test for categorical variables.
^ Mean ( ± SD).
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Univariate association for CT and clinical features with the KRAS
rearrangement in the validation set are listed in Table 3. At univariate
analysis KRAS+ rearrangement confirmed an association with round
shape, emphysema and smoking. Smoking was the most associated
factor, with almost all KRAS+ patients being smokers (39/41; 95%)
compared to 35 smokers out of 47 KRAS- patients (74%).
Fig. 5 shows ROC curves for KRAS rearrangement prediction in the
validation set, showing that, as previously demonstrated in the training
set, the AUC for the full model was higher than that of nodules in non-
tumour lobes (p = 0.05), whereas it was similar to that for shape
(p = 0.24) and smoking (p = 0.99).
4. Discussion
This study validated the performance of a model based on radi-
ological features and clinical features for prediction of EGFR mutation
and/or KRAS rearrangement in an independent external group of 122
lung cancer patients (validation set) [6].
The radiomic process can rely on the evaluation of quantitative
features, radiological qualitative features, or both [4]. On the one hand,
the development of different software to extract quantitative features
from digital images in DICOM format [10] has aroused growing interest
in the field of radiomics, with a focus on quantitative features. On the
other, previous studies have demonstrated that radiological features,
Fig. 2. ROC curve for EGFR mutation prediction in the validation set, applying
the prediction model of the training set [6].
Note: Area Under the Curve (AUC) for the training cohort was 0.82 [6]; AUC
(95%CI) for the validation cohort = 0.82 (0.69–0.95).
*−1.2103–0.2136*(maximum diameter [cm])+0.8882*(females)+1.5168*(air
bronchogram)+0.9183*(pleural retraction)-1.3695*(fibrosis)-1.7150(smoking).
Except for diameter, coefficients were multiplied by 1 if the condition was pre-
sent and by 0 if the condition was absent.
Fig. 3. ROC curve for KRAS mutation prediction in the validation set, applying
the prediction model of the training set [6].
Note: Area Under the Curve for the training cohort was 0.67 [6]; AUC (95%CI)
for the validation cohort = 0.60 (0.48–0.72)
*−2.0544 + 0.6071*(complex shape)+0.8756*(round shape)+0.6389*(no-
dules in non-tumour lobes)+0.7936*(smoking). Coefficients were multiplied
by 1 if the condition was present and by 0 if the condition was absent.
Table 2
Association of patient, tumour and CT features with the EGFR mutation in the
validation set: univariate analysis.
EGFR
− N (%) + N (%) P value*
Maximum diameter^ 48.82
( ± 28.76)
51.26
( ± 22.66)
0.63
Age^ 60.74 ( ± 1.04) 63.44
( ± 12.17)
0.21
Sex 0.11
Male 34 (46%) 15 (31%)
Female 40 (54%) 33 (69%)
Lobe 0.40
LSD 15 (21%) 12 (25%)
LM 0 (0%) 1 (2%)
LID 15 (21%) 15 (31%)
LSS 23 (32%) 13 (27%)
LIS 12 (17%) 4 (8%)
Mixed 7 (10%) 3 (6%)
Shape 0.006
Complex 29 (39%) 24 (50%)
Round 17 (23%) 1 (2%)
Oval 28 (38%) 23 (48%)
Margins 0.45
Smooth 11 (15%) 6 (13%)
Lobulated 5 (7%) 1 (2%)
Spiculated/irregular 58 (78%) 41 (85%)
Peripheral halo 11 (15%) 3 (6%) 0.14
Density 0.07
Partially solid 8 (11%) 1 (2%)
Solid 66 (89%) 47 (98%)
Cavitation 6 (8%) 4 (8%) 0.96
Internal air bronchogram 21 (28%) 22 (46%) 0.05
Thickening of the adjacent pleura 38 (52%) 34 (74%) 0.02
Necrosis 15 (20%) 13 (27%) 0.38
Satellite nodules in primary tumour lobe 27 (36%) 21 (44%) 0.42
Nodules in non-tumour lobes 35 (47%) 25 (52%) 0.61
Pleural retraction 52 (70%) 42 (88%) 0.03
Lesion location 0.30
Central 32 (44%) 26 (54%)
Peripheral 40 (56%) 22 (46%)
Calcifications 2 (3%) 1 (2%) 0.83
Emphysema 31 (42%) 5 (10%) 0.0002
Fibrosis 13 (18%) 5 (10%) 0.25
Pleural contact 52 (71%) 39 (81%) 0.21
Pleural effusion 22 (30%) 18 (38%) 0.37
Smoking∞ 65 (97%) 9 (43%) <0.0001
CI = Confidence Interval; LLL = Left Lower Lobe; LUL = Left Upper Lobe;
ML = Medium Lobe; RLL = Right Lower Lobe; RUL = Right Upper Lobe.
Note: significant ORs and p-values are in bold.
* T-test for continuous variables; Chi-Square test for categorical variables.
^ Mean ( ± SD).
∞ Smoking data available for N = 67 EGFR- and N = 21 EGFR+ patients.
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corresponding to descriptive features more familiar for radiologists,
may be associated with tumour biology [6]. Subsequent studies further
demonstrated that the combination of radiological qualitative and
quantitative features, and the inclusion of clinical information
strengthens the robustness of radiomic models [4].
Validation of a model in an external cohort of patients gives ro-
bustness and consistency to the model itself in all cases [11]. Based on
previous papers, a reasonable number of patients to be included in a
radiomics analysis should be ten for each feature in a model based on
binary classifiers [4], thus large cohorts of patients for training and
validation studies are needed. Moreover, it is well known that model
fitting is optimal in the training set used to build the model itself, while
validation in an external cohort provides more reliable fitting estimates
[12]. Finally, external validation will determine the transportability of
the model in different locations consisting of plausibly similar in-
dividuals (different case-mix) [13]. Accordingly, the sharing of image
data among different centres is appropriate and valuable. The best
models are those that can accommodate additional clinical or genomic
covariates, along with radiological and quantitative features, taking
into account differences in acquisitions, protocols and patients’ popu-
lations [4,8,14–16].
This study validated a model for prediction of the EGFR mutation
and KRAS rearrangement in NSCLC, based on radiological and clinical
features. In the training cohort, we found that an air bronchogram,
pleural retraction, and small size (radiological features), were asso-
ciated with the EGFR mutation [6]. In the same cohort major clinical
features, concordant with data already known in the literature [17],
were: sex (females more frequently mutated than males), smoking
history (non smokers more frequently mutated than smokers), emphy-
sema and fibrosis (both less frequent in mutated patients than in non-
mutated ones).
As shown in the results section, for EGFR mutation prediction, the
AUC for our validation set was 0.82 (0.69–0.95). This result shows a
better performance of the model presented by a previous study where
discrimination between EGFR+ and EGFR-, based on a radiomic
quantitative signature, showed an AUC = 0.69, although it is of note
that the authors demonstrated an improvement of the performance
when they combined the radiomic signature with a clinical model
(AUC = 0.75) [18]. Likewise, Liu et al demonstrated that a multiple
logistic regression model adding radiomic features to a clinical model
resulted in a significant improvement of predicting power, by in-
creasing the AUC from 0.667 to 0.709 (P < .0001) [19]. Despite the
differences in the overall performance of the models, that may require
further validations, it is clear that the combination of clinical and
radiological features improves the output of all the model assessed.
In our validation cohort, internal air bronchogram and pleural re-
traction (radiological features), along with absence of emphysema and
of smoking (clinical features), were significantly associated with the
EGFR+ mutation. Indeed, when using in the validation cohort the same
cutoff for the model score of -1.21923 used in the training cohort, the
SE, SP and DA were 70%, 83% and 80% respectively, thus confirming,
although a DA of 80% is still not perfect, the importance of the
abovementioned radiological features for association with EGFR+
mutation. In the validation cohort, a major role was observed for
smoking history: the prediction accuracy for the model including only
smoking data was similar to that of the full model including both
Fig. 4. ROC curves for EGFR mutation prediction between each characteristic
significantly associated with EGFR in the validation set.
*estimates obtained in the training cohort are applied
Table 3
Association of CT and clinical features with the KRASmutation in the validation
set: univariate analysis.
KRAS
−
N (%)
+
N (%)
Pvalue*
Maximum diameter^ 48.82
( ± 28.76)
51.26
( ± 22.66)
0.49
Age^ 60.74
( ± 11.04)
63.44
( ± 12.17)
0.15
Sex 0.30
Male 34 (44%) 15 (34%)
Female 44 (56%) 29 (66%)
Lobe 0.46
LSD 21 (27%) 6 (14%)
LM 1 (1%) 0 (0%)
LID 20 (26%) 10 (23%)
LSS 21 (27%) 15 (35%)
LIS 9 (12%) 7 (16%)
Mixed 5 (6%) 5 (12%)
Shape 0.009
Complex 39 (50%) 14 (32%)
Round 6 (8%) 12 (27%)
Oval 33 (42%) 18 (41%)
Margins 0.23
Smooth 10 (13%) 7 (16%)
Lobulated 2 (3%) 4 (9%)
Spiculated/irregular 66 (85%) 33 (75%)
Peripheral halo 7 (9%) 7 (16%) 0.25
Density 0.21
Partially solid 4 (5%) 5 (11%)
Solid 74 (95%) 39 (89%)
Cavitation 7 (9%) 3 (7%) 0.68
Internal air bronchogram 30 (38%) 13 (30%) 0.32
Thickening of the adjacent pleura 50 (67%) 22 (50%) 0.07
Necrosis 16 (21%) 12 (27%) 0.39
Satellite nodules in primary tumour lobe 34 (44%) 14 (32%) 0.20
Nodules in non-tumour lobes 38 (49%) 22 (50%) 0.89
Pleural retraction 63 (81%) 31 (70%) 0.19
Lesion location 0.10
Central 42 (54%) 16 (38%)
Peripheral 36 (46%) 26 (62%)
Calcifications 2 (3%) 1 (2%) 0.92
Emphysema 18 (23%) 18 (42%) 0.03
Fibrosis 11 (14%) 7 (16%) 0.77
Pleural contact 59 (76%) 32 (74%) 0.88
Pleural effusion 30 (38%) 10 (23%) 0.08
Smoking∞ 35 (74%) 39 (95%) 0.008
CI = Confidence Interval; LLL = Left Lower Lobe; LUL = Left Upper Lobe;
ML = Medium Lobe; RLL = Right Lower Lobe; RUL = Right Upper Lobe.
Note: significant ORs and p-values are in bold.
* T-test for continuous variables; Chi-Square test for categorical variables.
^ Mean ( ± SD).
∞ Smoking data available for N = 47 KRAS- and N = 41 KRAS+ patients.
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clinical and CT features. This is likely due to the fact that in the vali-
dation set smoking history was positive for the large majority of the
subjects with available data (84%), with a possibility of oversampling
of smokers in this cohort. Because of the known association between
smoking and EGFR [20] this oversampling may “conceal” the effect of
other possible predictors.
In the training cohort, as well as in the validation cohort, the pre-
sence of an air bronchogram was significantly associated with the
presence of EGFR mutation. This result is concordant with previous
studies demonstrating that effective EGFR mutations are frequently
accompanied by air bronchogram [6,21,22].
In this study, we validated the association between pleural retrac-
tion and EGFR mutation. This result is in agreement with previous
studies, where multivariable regression analyses indicated that pleural
retraction was one of the prognostic factors for harboring EGFR muta-
tion [23].
In the training cohort there was a significant association between
small size and EGFR, that was concordant with other studies [24].
However, in the validation cohort, the association between small lesion
diameter and EGFR+ mutation was not confirmed at the univariate
analysis. This might be due to the different type of accrual of the two
cohorts. Indeed, the training cohort was selected in an oncological
hospital, according to the availability of assessment of gene mutations
or rearrangements, regardless of cancer stage. Instead, the validation
cohort included patients from hospitals in the southern region of the
Netherlands, mainly with advanced lung cancer (because in the Neth-
erlands only patients with stage IIIb or IV receiving a palliative treat-
ment are tested for EGFR or KRAS mutations).
The absence of emphysema was confirmed as feature associated
with presence of EGFR mutation in the training cohort as well as in the
validation cohort. These results are concordant with other studies in the
literature where the EGFRmutation group was not prone to emphysema
(p = 0.002) [24,25], as well as in agreement with other authors that
quantified 30 detailed CT features, demonstrating that severe periph-
eral emphysema was more likely associated with wild-type EGFR tu-
mors [22].
The model for prediction of the KRAS rearrangement in the training
cohort demonstrated a significant association with radiological fea-
tures, such as round shape and nodules in non-tumour lobes, along with
smoking history. In the validation cohort, univariate analysis confirmed
the association of the KRAS+ rearrangement with round lesion shape
and smoking history, whereas the association with nodules in non-tu-
mour lobes was not confirmed. As mentioned in the analysis of the
training cohort, the statistical significance of nodules in non-tumour
lobes was close to unity, therefore this association needed a validation
[6]. Nodules in non-tumour lobes refer to a haematogenous dis-
semination of cells, usually seen in more aggressive tumours. Since the
KRAS rearrangement is associated with a worse prognosis [25,26], this
may coexist with haematogenous dissemination, and not necessarily
with the KRAS rearrangement. In the validation group, smoking history
confirmed its association with the KRAS+ rearrangement, as known in
the literature [27,28].
As for EGFR+ prediction, the full model comparing the ROC curves
for association of features and KRAS+ rearrangement did not show a
significant improvement when compared to a model based only on
round shape or smoking.
This study has some limitations. The main drawback is the lack of
detailed information on smoking history in the validation group.
Indeed, smoking was an important feature in the model built on the
training cohort, but its importance was overestimated in the validation
group, where the majority of patients were smokers. However, it does
not affect the univariate analysis, where each single feature has its own
importance, and the main associations of radiological and clinical fea-
tures with the EGFR+ mutation and KRAS+ rearrangement were
confirmed. Another limitation is the lack of uniformity in the selection
of patients, and the relative lack of stratification for stages. As already
mentioned, this might have influenced the lack of significance of small
size for lesion association with EGFR. However, the aim of this study
was to validate a prognostic model for prediction of the EGFR+ mu-
tation and KRAS+ rearrangement, irrespective of disease stage and
therapy.
In conclusion, this study validated in NSCLC patients the association
of radiological features (internal air bronchogram,and pleural retrac-
tion) and clinical features (lack of emphysema and smoking) with the
EGFR+ mutation and of round shape and smoking with KRAS muta-
tion. The weight of smoking history alone is however as important as
that of imaging features.
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